May 24, 2016 / 10:06 AM / a year ago

BRIEF-Glaxosmithkline and Innoviva report positive headline results in Salford Lung study

May 24 (Reuters) - Glaxosmithkline Plc :

* Co and Innoviva announced positive headline results from innovative salford lung study in chronic obstructive pulmonary disease

* Study showed that relvar  ellipta  100/25mcg achieved a superior reduction in exacerbations versus usual care, in patients with copd

* Analyses remain ongoing and will be subject of future publications and presentations

* Second salford lung study is currently being conducted in asthma patients, with results expected in 2017

* For primary effectiveness analysis, in patients treated there was statistically significant reduction in rate of moderate or severe exacerbations Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below